Annual screening beneficial in high-risk PCa patients

Late-breaking data from ESMO 2024 suggest ipilimumab / nivolumab may be a new standard of care for non-clear cell renal cell cancer.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

Investigators observed promising clinical effect with the EGFR / HER3 bispecific antibody-drug conjugate.

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

Data from the TiNivo-2 trial showed a median progression-free survival of 5.7 months in the tivozanib plus nivolumab arm vs 7.4 months in tivozanib monotherapy arm.

Based on preliminary data, the Safety Review Committee has recommended that the trial proceed with dosing the final 3 patients in the cohort.